{"id":"W4293786422","doi":"10.1182/bloodadvances.2022007779","title":"Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Novartis Pharmaceuticals Corporation","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003706924,0.0001538958,0.0004254365,0.0001867858,0.0001006853,0.000007798048,0.00013,0.00002147064,0.000263525],"category_scores_gemma":[0.0001025355,0.0001276379,0.00003568531,0.0004584634,0.00009580891,0.00009309017,0.0001363884,0.0002826909,0.000001232413],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007488937,"about_ca_system_score_gemma":0.0001395023,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008392597,"about_ca_topic_score_gemma":0.00008115916,"domain_scores_codex":[0.9979794,0.0001335263,0.0004527278,0.0004024508,0.0007491394,0.0002827649],"domain_scores_gemma":[0.9991339,0.0001383155,0.0001610768,0.0003757064,0.0000791721,0.0001117701],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1924521,0.06042449,0.5724483,0.0001977968,0.0005303771,0.0006347859,0.007074003,0.0004280827,0.002865063,0.00002010133,0.00007578406,0.1628492],"study_design_scores_gemma":[0.3343129,0.01990524,0.6347353,0.00006559044,0.0001724352,0.00002759882,0.001710509,0.00005485067,0.001278366,0.00001006968,0.007498298,0.0002287888],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955843,0.000975146,0.000002513281,0.00007062562,0.00004659235,0.001502788,0.00009250258,0.00002574507,0.001699748],"genre_scores_gemma":[0.9984875,0.0001019402,0.00009555269,0.00003270852,0.00002926357,0.00004583397,0.00006830039,0.00002813081,0.001110817],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1626204,"threshold_uncertainty_score":0.5204923,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01465723839911933,"score_gpt":0.3169344250916463,"score_spread":0.302277186692527,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}